Hypoadiponectinemia: A Link Between Visceral Obesity and Metabolic Syndrome

Overview

Journal J Nutr Metab

Publisher Wiley

Date 2011 Oct 21

PMID 22013516

Citations 21

Authors

Tiziana Di Chiara

Christiano Argano

Salvatore Corrao

Rosario Scaglione

Giuseppe Licata

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome (MetS) represents a combination of cardiometabolic risk factors, including visceral obesity, glucose intolerance or type 2 diabetes, elevated triglycerides, reduced HDL cholesterol, and hypertension. MetS is rapidly increasing in prevalence worldwide as a consequence of the "epidemic" obesity, with a considerable impact on the global incidence of cardiovascular disease and type 2 diabetes. At present, there is a growing interest on the role of visceral fat accumulation in the occurrence of MetS. In this review, the effects of adipocytokines and other proinflammatory factors produced by fat accumulation on the occurrence of the MetS have been also emphasized. Accordingly, the "hypoadiponectinemia" has been proposed as the most interesting new hypothesis to explain the pathophysiology of MetS.

Citing Articles

The correlation between indirect calorimetry data and the metabolic syndrome development in men and women.

Roudi F, Darroudi S, Saghi E, Hosseini S, Kohantorabi M, Rezvani A J Diabetes Metab Disord. 2024; 24(1):1.

PMID: 39686919 PMC: 11646228. DOI: 10.1007/s40200-024-01521-4.

Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence.

Corrao S, Pollicino C, Maggio D, Torres A, Argano C Front Endocrinol (Lausanne). 2024; 15:1402583.

PMID: 38978621 PMC: 11228148. DOI: 10.3389/fendo.2024.1402583.

Analysis of the adiponectin paradox in healthy older people.

Walowski C, Herpich C, Enderle J, Braun W, Both M, Hasler M J Cachexia Sarcopenia Muscle. 2022; 14(1):270-278.

PMID: 36401062 PMC: 9891976. DOI: 10.1002/jcsm.13127.

The "Diabetes Comorbidome": A Different Way for Health Professionals to Approach the Comorbidity Burden of Diabetes.

Corrao S, Natoli G, Nobili A, Mannucci P, Perticone F, Arcoraci V Healthcare (Basel). 2022; 10(8).

PMID: 36011116 PMC: 9408695. DOI: 10.3390/healthcare10081459.

Anti-Diabesity Middle Eastern Medicinal Plants and Their Action Mechanisms.

Saad B, Kmail A, Haq S Evid Based Complement Alternat Med. 2022; 2022:2276094.

PMID: 35899227 PMC: 9313926. DOI: 10.1155/2022/2276094.

References

Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K . PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50(9):2094-9. DOI: 10.2337/diabetes.50.9.2094. View

Ohashi K, Ouchi N, Matsuzawa Y . Adiponectin and hypertension. Am J Hypertens. 2010; 24(3):263-9. DOI: 10.1038/ajh.2010.216. View

Yang W, Jeng C, Wu T, Tanaka S, Funahashi T, Matsuzawa Y . Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002; 25(2):376-80. DOI: 10.2337/diacare.25.2.376. View

Vozarova B, Stefan N, Lindsay R, Krakoff J, Knowler W, Funahashi T . Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes. 2002; 51(10):2964-7. DOI: 10.2337/diabetes.51.10.2964. View

Kaplan N . The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989; 149(7):1514-20. DOI: 10.1001/archinte.149.7.1514. View

Duncan B, Schmidt M, Pankow J, Bang H, Couper D, Ballantyne C . Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004; 53(9):2473-8. DOI: 10.2337/diabetes.53.9.2473. View

Matsuzawa Y, Funahashi T, Kihara S, Shimomura I . Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2003; 24(1):29-33. DOI: 10.1161/01.ATV.0000099786.99623.EF. View

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86(5):1930-5. DOI: 10.1210/jcem.86.5.7463. View

Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N . Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23(1):85-9. DOI: 10.1161/01.atv.0000048856.22331.50. View

10.

Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H . Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006; 48(7):1369-77. DOI: 10.1016/j.jacc.2006.06.053. View

11.

Reaven G . Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12):1595-607. DOI: 10.2337/diab.37.12.1595. View

12.

Haffner S . Insulin and blood pressure: fact or fantasy?. J Clin Endocrinol Metab. 1993; 76(3):541-3. DOI: 10.1210/jcem.76.3.8445008. View

13.

Lawlor D, Davey Smith G, Ebrahim S, Thompson C, Sattar N . Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005; 90(10):5677-83. DOI: 10.1210/jc.2005-0825. View

14.

Okamoto Y, Folco E, Minami M, Wara A, Feinberg M, Sukhova G . Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2007; 102(2):218-25. DOI: 10.1161/CIRCRESAHA.107.164988. View

15.

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83. DOI: 10.1006/bbrc.1999.0255. View

16.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R . Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001; 507(2):142-6. DOI: 10.1016/s0014-5793(01)02960-x. View

17.

Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K . Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004; 43(6):1318-23. DOI: 10.1161/01.HYP.0000129281.03801.4b. View

18.

Lindsay R, Funahashi T, Krakoff J, Matsuzawa Y, Tanaka S, Kobes S . Genome-wide linkage analysis of serum adiponectin in the Pima Indian population. Diabetes. 2003; 52(9):2419-25. DOI: 10.2337/diabetes.52.9.2419. View

19.

Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-7. DOI: 10.1001/jama.291.14.1730. View

20.

Tarquini R, Lazzeri C, Laffi G, Gensini G . Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med. 2007; 2(3):165-76. DOI: 10.1007/s11739-007-0027-9. View